Journal article
Growth Differentiation Factor 15 as a Novel Biomarker for Metformin
Abstract
OBJECTIVE: Metformin is a commonly used glucose-lowering drug. However, apart from glycemic measures, no biomarker for its presence or dose has been identified.
RESEARCH DESIGN AND METHODS: A total of 237 biomarkers were assayed in baseline serum from 8,401 participants (2,317 receiving metformin) in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial. Regression models were used to identify biomarkers for metformin use.
Authors
Gerstein HC; Pare G; Hess S; Ford RJ; Sjaarda J; Raman K; McQueen M; Lee S; Haenel H; Steinberg GR
Journal
Diabetes Care, Vol. 40, No. 2, pp. 280–283
Publisher
American Diabetes Association
Publication Date
February 1, 2017
DOI
10.2337/dc16-1682
ISSN
0149-5992